FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973016412> ?p ?o ?g. }

• W2973016412 abstract "Methyl-CpG binding domain protein 1 (MBD1), which couples DNA methylation to transcriptional repression, has been implicated in transcriptional regulation, heterochromatin formation, genomic stability, cell cycle progression and development. It has also been proven that MBD1 is involved in tumor development and progression. However, whether MBD1 is involved in tumorigenesis, especially in gallbladder cancer, is totally unknown.Human GBC-SD and SGC996 cells were used to perform experiments. Invasion, wound healing and colony formation assays were performed to evaluate cell viability. A CCK-8 assay was performed to assess gallbladder cancer cell viability after gemcitabine treatment. Western blot analysis was used to evaluate changes in protein expression. Human gallbladder cancer tissues and adjacent nontumor tissues were subjected to immunohistochemical staining to detect protein expression.We found that MBD1 expression was significantly upregulated in gallbladder cancer tissues compared with that in surrounding normal tissues according to immunohistochemical analysis of 84 surgically resected gallbladder cancer specimens. These data also indicated that higher MBD1 expression was correlated with lymph node metastasis and poor survival in gallbladder cancer patients. Overexpression and deletion in vitro validated MBD1 as a potent oncogene promoting malignant behaviors in gallbladder cancer cells, including invasion, proliferation and migration, as well as epithelial-mesenchymal transition. Studies have demonstrated that epithelial-mesenchymal transition is common in gallbladder cancer, and it is well known that drug resistance and epithelial-mesenchymal transition are very closely correlated. Herein, our data show that targeting MBD1 restored gallbladder cancer cell sensitivity to gemcitabine chemotherapy.Taken together, the results of our study revealed a novel function of MBD1 in gallbladder cancer tumor development and progression through participation in the gallbladder cancer epithelial-mesenchymal transition program, which is involved in resistance to gemcitabine chemotherapy. Thus, MBD1 may be a potential therapeutic target for gallbladder cancer." @default.
• W2973016412 created "2019-09-19" @default.
• W2973016412 creator A5000579442 @default.
• W2973016412 creator A5002995123 @default.
• W2973016412 creator A5003145621 @default.
• W2973016412 creator A5021423929 @default.
• W2973016412 creator A5032653173 @default.
• W2973016412 creator A5038464428 @default.
• W2973016412 creator A5045831121 @default.
• W2973016412 creator A5046066219 @default.
• W2973016412 creator A5066935433 @default.
• W2973016412 date "2019-09-09" @default.
• W2973016412 modified "2023-10-14" @default.
• W2973016412 title "MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine" @default.
• W2973016412 cites W1520127479 @default.
• W2973016412 cites W1589114640 @default.
• W2973016412 cites W168683249 @default.
• W2973016412 cites W1777166914 @default.
• W2973016412 cites W1968129693 @default.
• W2973016412 cites W1974352623 @default.
• W2973016412 cites W1974399646 @default.
• W2973016412 cites W1979089897 @default.
• W2973016412 cites W1982451710 @default.
• W2973016412 cites W2005745857 @default.
• W2973016412 cites W2016360721 @default.
• W2973016412 cites W2023604857 @default.
• W2973016412 cites W2025988925 @default.
• W2973016412 cites W2030513330 @default.
• W2973016412 cites W2039727733 @default.
• W2973016412 cites W2058468989 @default.
• W2973016412 cites W2063176473 @default.
• W2973016412 cites W2080221524 @default.
• W2973016412 cites W2096855980 @default.
• W2973016412 cites W2106550415 @default.
• W2973016412 cites W2108015399 @default.
• W2973016412 cites W2115261608 @default.
• W2973016412 cites W2116323116 @default.
• W2973016412 cites W2119802952 @default.
• W2973016412 cites W2123247856 @default.
• W2973016412 cites W2127307810 @default.
• W2973016412 cites W2128889451 @default.
• W2973016412 cites W2130184016 @default.
• W2973016412 cites W2132577566 @default.
• W2973016412 cites W2144967170 @default.
• W2973016412 cites W2153017356 @default.
• W2973016412 cites W2302125586 @default.
• W2973016412 cites W2347189260 @default.
• W2973016412 cites W2605183923 @default.
• W2973016412 cites W2606001457 @default.
• W2973016412 cites W2612911334 @default.
• W2973016412 cites W2730473913 @default.
• W2973016412 cites W2745824859 @default.
• W2973016412 cites W2768049487 @default.
• W2973016412 cites W2769500636 @default.
• W2973016412 cites W2769742637 @default.
• W2973016412 cites W2781525129 @default.
• W2973016412 cites W2789644588 @default.
• W2973016412 cites W2792142773 @default.
• W2973016412 cites W2889296926 @default.
• W2973016412 cites W2937317161 @default.
• W2973016412 doi "https://doi.org/10.1186/s12935-019-0948-1" @default.
• W2973016412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6734348" @default.
• W2973016412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31516389" @default.
• W2973016412 hasPublicationYear "2019" @default.
• W2973016412 type Work @default.
• W2973016412 sameAs 2973016412 @default.
• W2973016412 citedByCount "4" @default.
• W2973016412 countsByYear W29730164122020 @default.
• W2973016412 countsByYear W29730164122022 @default.
• W2973016412 countsByYear W29730164122023 @default.
• W2973016412 crossrefType "journal-article" @default.
• W2973016412 hasAuthorship W2973016412A5000579442 @default.
• W2973016412 hasAuthorship W2973016412A5002995123 @default.
• W2973016412 hasAuthorship W2973016412A5003145621 @default.
• W2973016412 hasAuthorship W2973016412A5021423929 @default.
• W2973016412 hasAuthorship W2973016412A5032653173 @default.
• W2973016412 hasAuthorship W2973016412A5038464428 @default.
• W2973016412 hasAuthorship W2973016412A5045831121 @default.
• W2973016412 hasAuthorship W2973016412A5046066219 @default.
• W2973016412 hasAuthorship W2973016412A5066935433 @default.
• W2973016412 hasBestOaLocation W29730164121 @default.
• W2973016412 hasConcept C121608353 @default.
• W2973016412 hasConcept C126322002 @default.
• W2973016412 hasConcept C142724271 @default.
• W2973016412 hasConcept C204232928 @default.
• W2973016412 hasConcept C2776534502 @default.
• W2973016412 hasConcept C2777148285 @default.
• W2973016412 hasConcept C2779013556 @default.
• W2973016412 hasConcept C2780258809 @default.
• W2973016412 hasConcept C2781018059 @default.
• W2973016412 hasConcept C29537977 @default.
• W2973016412 hasConcept C502942594 @default.
• W2973016412 hasConcept C555283112 @default.
• W2973016412 hasConcept C71924100 @default.
• W2973016412 hasConcept C76419328 @default.
• W2973016412 hasConcept C86803240 @default.
• W2973016412 hasConcept C96232424 @default.
• W2973016412 hasConceptScore W2973016412C121608353 @default.
• W2973016412 hasConceptScore W2973016412C126322002 @default.
• W2973016412 hasConceptScore W2973016412C142724271 @default.

• next